Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

In this educational workshop, Parexel regulatory experts, all former regulators, provide a comprehensive view of anti-drug conjugates (ADCs) for the treatment of cancer - from non-clinical, CMC, and clinical perspectives. In this 90-minute educational session, we explore how ADCs are developed and characterized in the non-clinical stage, the critical considerations, and challenges in manufacturing processes (CMC), and the exciting clinical developments shaping the landscape of cancer therapy. Join us as we delve into the multidimensional aspects of ADCs and their potential to revolutionize cancer treatment.

Return to Insights Center

Related Insights

Webinar

Navigating the complexities of AML drug development

Oct 30, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Whitepaper

How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Jun 28, 2023

Blog

Population variability: important considerations in vaccine development

Jun 14, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Related Insights

Webinar

Navigating the complexities of AML drug development

Oct 30, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Show more